Our Fine Chemicals team in the US has applied its manufacturing process knowledge and complex chemistry expertise to develop a new active pharmaceutical ingredient (API) which is being used in treatments for depression

Developing active pharmaceutical products at our Fine Chemicals facility in West Deptford, US
Developing active pharmaceutical products at our Fine Chemicals facility in West Deptford, US

This process innovation has enabled the customer to develop medications which could be used to treat multiple illnesses and is an innovation that has the potential to benefit many people.

The customer is new to Johnson Matthey and the team in the US studied the customer's needs so that they could tailor their offering to win the business.

Most medicines are created using organic compound base materials, which we turn into APIs through several processes including chemical synthesis (the manipulation of the base materials through chemical reactions). The resulting APIs are small molecules that bind to specific biological targets within the body and can be used in our customers' products.

Tailored products

By building on one of the core molecules we already produce, the team was able to convert that molecule into the new product the customer required. The molecule Johnson Matthey is now producing for this customer is used in the APIs for several different medications, including the new product designed to combat depression.

The process for making this new product, which is also more cost effective and efficient, has demonstrated our complex chemistry skills and customer focused approach, giving us the potential to work with the customer on other products in the future.